DE60233668D1 - Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe - Google Patents

Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe

Info

Publication number
DE60233668D1
DE60233668D1 DE60233668T DE60233668T DE60233668D1 DE 60233668 D1 DE60233668 D1 DE 60233668D1 DE 60233668 T DE60233668 T DE 60233668T DE 60233668 T DE60233668 T DE 60233668T DE 60233668 D1 DE60233668 D1 DE 60233668D1
Authority
DE
Germany
Prior art keywords
propranolol
multiparticular
active ingredients
pharmaco
time controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233668T
Other languages
English (en)
Inventor
Phillip J Percel
Gopi M Venkatesh
Krishna S Vishnupad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals Inc
Original Assignee
Eurand America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand America Inc filed Critical Eurand America Inc
Application granted granted Critical
Publication of DE60233668D1 publication Critical patent/DE60233668D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE60233668T 2001-10-04 2002-10-02 Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe Expired - Lifetime DE60233668D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/971,167 US6500454B1 (en) 2001-10-04 2001-10-04 Timed, sustained release systems for propranolol
PCT/US2002/031535 WO2003028708A1 (en) 2001-10-04 2002-10-02 Timed, sustained release multi-particulate dosage forms of propranolol

Publications (1)

Publication Number Publication Date
DE60233668D1 true DE60233668D1 (de) 2009-10-22

Family

ID=25518009

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233668T Expired - Lifetime DE60233668D1 (de) 2001-10-04 2002-10-02 Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe

Country Status (12)

Country Link
US (2) US6500454B1 (de)
EP (1) EP1432411B1 (de)
JP (1) JP4369752B2 (de)
KR (1) KR101090719B1 (de)
AT (1) ATE442134T1 (de)
AU (1) AU2002330211B2 (de)
CA (1) CA2462637C (de)
DE (1) DE60233668D1 (de)
ES (1) ES2333306T3 (de)
MX (1) MXPA04003234A (de)
NO (1) NO335070B1 (de)
WO (1) WO2003028708A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7967756B2 (en) * 2003-09-18 2011-06-28 Cardiac Pacemakers, Inc. Respiratory therapy control based on cardiac cycle
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
AU2005212005A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US20060173081A1 (en) * 2004-10-01 2006-08-03 Rotenberg Keith S Treating morning migraines with propranolol
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (de) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Geschmacksverdeckende pharmazeutische Zusammensetzungen mit magenlöslichen Porenbildnern
US20060099259A1 (en) * 2004-11-05 2006-05-11 Grant Heinicke Propranolol formulations
US20060099258A1 (en) * 2004-11-05 2006-05-11 Grant Heinicke Propranolol formulations
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
ATE481096T1 (de) * 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
AU2013273835B2 (en) * 2005-05-02 2016-07-07 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US11311490B2 (en) 2005-08-10 2022-04-26 Add Advanced Drug Delivery Technologies Ltd. Oral preparation with controlled release
US20070196491A1 (en) * 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
NZ570039A (en) * 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
KR20080095873A (ko) * 2006-02-13 2008-10-29 반다 파마슈티칼즈, 인코퍼레이티드. 이미다졸릴알킬-피리딘의 안정한 제제
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
BRPI0711221A2 (pt) * 2006-05-26 2012-03-13 Auspex Pharmaceuticals, Inc Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
BRPI0716196A2 (pt) * 2006-08-31 2013-11-12 Eurand Inc Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
WO2008070670A2 (en) * 2006-12-04 2008-06-12 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
JP5729808B2 (ja) 2007-12-13 2015-06-03 ヴァンダ ファーマシューティカルズ インコーポレイテッド αアドレナリン受容体介在状態を治療する方法及び組成物
EP2222300B1 (de) 2007-12-13 2014-06-11 Vanda Pharmaceuticals Inc. Verfahren und zusammensetzung zur behandlung eines zustands, der durch den serotonin-rezeptor vermittelt wird
JP5878022B2 (ja) * 2009-02-23 2016-03-08 アデア ファーマスーティカルズ，インコーポレイテッド 抗コリン薬を具える放出制御組成物
WO2011066287A1 (en) 2009-11-30 2011-06-03 Eurand, Inc. Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
CA2782285A1 (en) 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20120282335A1 (en) 2010-12-02 2012-11-08 Aptalis Pharmatech Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
WO2015004617A1 (en) * 2013-07-09 2015-01-15 Ranbaxy Laboratories Limited Extended-release pharmaceutical compositions of metoprolol
CN105287394A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸普萘洛尔缓释微丸及其制备方法
WO2019046251A1 (en) 2017-08-28 2019-03-07 Adare Pharmaceuticals, Inc. TIZANIDINE FORMULATIONS
JP2019052115A (ja) * 2017-09-15 2019-04-04 国立研究開発法人理化学研究所 医薬組成物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48A (en) * 1836-10-11 Turnout fob
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4851229A (en) 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3684446D1 (de) 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
IE58401B1 (en) 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5376384A (en) 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6162463A (en) 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6039979A (en) 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol

Also Published As

Publication number Publication date
CA2462637A1 (en) 2003-04-10
JP2005508922A (ja) 2005-04-07
CA2462637C (en) 2010-12-07
NO20041740L (no) 2004-04-28
ES2333306T3 (es) 2010-02-19
WO2003028708A1 (en) 2003-04-10
AU2002330211B2 (en) 2007-02-01
US6500454B1 (en) 2002-12-31
NO335070B1 (no) 2014-09-01
JP4369752B2 (ja) 2009-11-25
EP1432411A1 (de) 2004-06-30
KR20040084890A (ko) 2004-10-06
KR101090719B1 (ko) 2011-12-08
MXPA04003234A (es) 2004-08-12
ATE442134T1 (de) 2009-09-15
US20030157173A1 (en) 2003-08-21
EP1432411B1 (de) 2009-09-09

Similar Documents

Publication Publication Date Title
DE60233668D1 (de) Multipartikuläre verabreichungsformen von propranolol mit zeitgesteuerter und verlängerter wirkstofffreigabe
PT1123700E (pt) Sistemas de libertacao de farmacos de cronometragem pulsavel
AP2002002410A0 (en) Hydrodynamically Balancing Oral Drug Delivery System
DE60334775D1 (de) Mehrstufiges orales arzneimittelsystem mit kontrollierter freisetzung
WO2003103637A3 (en) MODIFIED RELEASE MULTIPLE UNIT DRUG DELIVERY SYSTEMS
BRPI0311701B8 (pt) formulação farmacêutica de dosagem multiparticulada revestida com liberação controlada de lamotrigina
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
DE69826113D1 (de) R- und s- enantiomere getrennteteile enthaltende dosierungsformen
FI944035A0 (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
HUP0500097A3 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
DE60018629D1 (de) Carbamazepinformulierung mit verzögerter Freigabe
Chhabra et al. The essentials of chronopharmacotherapeutics
PT1171111E (pt) Granulado com teor elevado de l-carnitina ou de uma alcanoil l-carnitina particularmente adequado para a producao de comprimidos por compressao directa
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
DE60134883D1 (de) Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
Tiwari et al. AN OVERVIEW: SUSTAINED RELEASE DRUG DELIVERY TECHNOLOGIES WITH POLYMERIC SYSTEM.
Bharathi CHRONOTHERAPY: NEW APPROACH FOR TREATMENT
Wakelee-Lynch Interferon may offer first drug therapy for diabetic retinopathy. New research showing that alpha-interferon blocks new blood vessel formation in the iris of monkeys may point the way to new treatment for diabetes retinopathy
Califf Benefit the patient, manage the risk: a system goal
WO2003082342A1 (fr) Utilisation du gene k1aa0172 pour le traitement et le diagnostic de maladies et decouverte de medicaments
NO326141B1 (no) Fremgangsmate for behandling av isolert systolisk hypertensjon
LoBuono New osteoporosis drug is first to form bone
Agrawal Antisense oligonucleotides as gene expression modulators
Weiss A shot at youth.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1432411

Country of ref document: EP

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN, DE